Sterne Agee Sees Teva Pharmaceutical Outperformance Continuing
On Wednesday, Sterne Agee initiated coverage on shares of Teva Pharmaceutical Industries (NYSE: TEVA) with a Neutral rating and $53 price target.
Analyst Shibani Malhotra believes “strong conversion of Copaxone 20mg/ml to its 40mg/ml formulation is crucial.”
The analyst credits the stocks year-to-date outperformance (up 25 percent) to the company “signaling its willingness to consider a ‘transformational deal.'”
Shibani would prefer “to see management focus on execution of its realignment and cost-cutting strategy before embarking on any ambitious M&A.”
The stock is up one percent to $50.10 in Wednesday's trading.
Latest Ratings for TEVA
Date | Firm | Action | From | To |
---|---|---|---|---|
Feb 2022 | Barclays | Maintains | Equal-Weight | |
Jan 2022 | Argus Research | Downgrades | Buy | Hold |
Oct 2021 | Raymond James | Downgrades | Outperform | Market Perform |
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Shibani Malhotra Sterne AgeeAnalyst Color Analyst Ratings